Background - Ecubectedin (PM14) is a novel transcriptional inhibitor related to ecteinascidins family...In mice bearing MDA-MB-231, H526 and 22Rv1 tumors, complete tumor remissions were seen in 1/10 (lasting 103 days), 9/10 (lasting 220 days) and 7/10 (lasting 13 days) ecubectedin-treated animals, respectively.Conclusions - Ecubectedin is a novel transcriptional inhibitor that displays potent antiproliferative activity in different human solid cancer models in vitro and in vivo. The drug is currently in clinical development in Phase II trials.

almost 2 years ago

Preclinical

TNFA (Tumor Necrosis Factor-Alpha) • ANXA5 (Annexin A5)

ecubectedin (PM14)

over2years

PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=150, Recruiting, PharmaMar | Active, not recruiting --> Recruiting

over 2 years ago

Enrollment open

BRCA (Breast cancer early onset)

BRCA mutation

ecubectedin (PM14)

3years

PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=150, Active, not recruiting, PharmaMar | Recruiting --> Active, not recruiting

3 years ago

Clinical • Enrollment closed

BRCA (Breast cancer early onset)

BRCA mutation

ecubectedin (PM14)

3years

PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=150, Recruiting, PharmaMar

3 years ago

Clinical • New P1 trial

BRCA (Breast cancer early onset)

BRCA mutation

ecubectedin (PM14)